A Phase 3 interventional study of Bremelanotide and Placebo in Hypoactive Sexual Desire Disorder, sponsored by Kwang Dong Pharmaceutical co., ltd.. Completed at 1 site in Korea, Republic of. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-11-13.
Sponsored by Kwang Dong Pharmaceutical co., ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).
138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.
This study's enrollment of 193 is above the median of 100 across 114 interventional studies indexed under Sexual Dysfunctions, Psychological.
Browse Sexual Dysfunctions, Psychological studies →Kwang Dong Pharmaceutical co., ltd. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
[Main Inclusion Criteria]
[Main Exclusion Criteria]
Bremelanotide (BMT) subcutaneously (SC) via auto-injector for 8-weeks double-Blind period
Drug: Bremelanotide
Placebo subcutaneously (SC) via auto-injector for 4-weeks single-Blind period and for 8-weeks double-Blind period
Drug: Placebo
Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.
Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
Change from baseline to End of Study in the desire domain from the FSFI
Time frame: Baseline up to End of Study(8weeks)
Change from baseline to End of Study in FSDS-DAO (Item 13)
Time frame: Baseline up to End of Study(8weeks)
Change from Baseline to End of Study in the Number of Satisfying Sexual Events (SSEs) Associated With Study Drug Administration
Time frame: Baseline up to End of Study(8weeks)
Change from Baseline to End of Study in Mean Desire Score (Q3) From FSEP-R
Time frame: Baseline up to End of Study(8weeks)
Change from Baseline to End of Study in Mean Satisfaction With Desire Score (Q4) From FSEP-R
Time frame: Baseline up to End of Study(8weeks)
Change from Baseline to End of Study in the FSDS-DAO Total Score
Time frame: Baseline up to End of Study(8weeks)
Change from Baseline to End of study in the total FSFI score based on the 19 questions
The FSFI total score is on a scale ranging from 2 to 36. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.
Time frame: Baseline up to End of Study(8weeks)
Change in mean Level of Sexual Arousal from FSEP-R Q6
Time frame: Baseline up to End of Study(8weeks)
Change in mean Satisfaction with Sexual Arousal from FSEP-R Q7.
Time frame: Baseline up to End of Study(8weeks)
Change from Baseline to End of study in the scored time spent being concerned by difficulty with sexual arousal as measured by the FSDS-DAO Q14.
Time frame: Baseline up to End of Study(8weeks)
Change from Baseline to End of study in the arousal domain from the FSFI Q3 through Q6.
Time frame: Baseline up to End of Study(8weeks)
Change from Baseline to End of study in the total number of SSEs.
Time frame: Baseline up to End of Study(8weeks)
Change from baseline in the desire domain from the FSFI Q1 and Q2 using all available double-blind data (visit 4, 5)
Time frame: Baseline up to End of Study(8weeks)
Change from baseline in the score for feeling bothered by low sexual desire as measured by the FSDS -DAO Q13 using all available double-blind data(visit 4, 5)
Time frame: Baseline up to End of Study(8weeks)
Change from baseline in the number of SSEs associated with study drug using the entire 8 weeks of the double-blind phase.
Time frame: Baseline up to End of Study(8weeks)
Ran from May 2021 to primary completion in May 2023, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bremelanotide
Sexual Dysfunctions, Psychological →
Kwang Dong Pharmaceutical co., ltd.